OptiBiotix Health PLC Supply agreement with Pharmabiota Ltd (1577L)
July 17 2017 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 1577L
OptiBiotix Health PLC
17 July 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
LP(LDL) (R) supply agreement for New Zealand & Australia
with Pharmabiota Ltd
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it has agreed to develop and supply
three different products containing LP(LDL) (R), with minimum
initial purchase of 10,000 boxes of each, to Pharmabiota NZ Limited
("Pharmabiota").
Pharmabiota, based in New Zealand, was founded by pharmacist
Peter Lagan to provide high quality and scientifically validated
innovative products through its growing retail pharmacy partner
network throughout New Zealand and Australia.
This agreement covers the initial development and supply of
three products, packaged and released by Pharmabiota, containing
LP(LDL) (R) in different dosage forms and provides initial moderate
levels of income, growing to six figure revenues in the second
year, and a commitment of 10% annual growth. The deal reflects the
growing industry awareness in LP(LDL) (R) as a functional component
in a wide range of consumer healthcare and pharmaceutical products
worldwide.
This interest arises from OptiBiotix's innovative science, good
clinical data & strong key opinion leader support, and the
products ability to reduce both cholesterol and blood pressure. The
agreement is the first step outside Europe in a business to
business (B2B) strategy of bringing OptiBiotix's science together
with a partner's national brand portfolio and market presence to
serve multiple consumer healthcare and pharmaceutical markets
around the world.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce this agreement to develop and supply multiple consumer
products containing LP(LDL) (R) to Pharmabiota to be sold through
its extensive antipodean partner network. We see this as another
step in the Company's strategy of building multiple revenue streams
from LP(LDL) (R) ingredient supply (from our profit share with
Sacco), and as a component in high value white label and branded
formulations, across a range of national pharmacy and large
consumer health international partners. This is a low risk, low
cost approach, to accessing multiple consumer healthcare and
pharmaceutical markets around the world. We are at the start of the
commercialisation process but are really excited at the high level
of interest in our products and the prospect of building multiple
revenue streams, which if this strategy is successful, have the
potential to cumulatively generate substantive seven figure
revenues in the forthcoming years."
For further information. Please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRLLFISDIISLID
(END) Dow Jones Newswires
July 17, 2017 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024